Option chain shows key data for Bukit Jalil Global Acquisition 1 Ltd. - Rights's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bukit Jalil Global Acquisition 1 Ltd. - Rights.

Bukit Jalil Global Acquisition 1 Ltd. - Rights (NASDAQ:BUJAR) Stock, Option Chain

Bukit Jalil Global Acquisition 1 Ltd. - Rights

<p>Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the results from its Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for the treatment of MASH have been selected to be presented by Dr. Onno Holleboom in an oral plenary presentation at the upcoming Steatotic Liver Disease (SLD) Summit 2025 hosted by the European Association for the Study of the Liver (EASL) on January 23-25 in Estoril, Portugal.</p>
<p><strong>The abstract evaluates the impact of combining lanifibranor with empagliflozin on metabolic improvements in patients with MASH and type-2 diabetes (T2D). </strong>The LEGEND trial, a multi-center, randomized, placebo-controlled Phase II Proof-of-Concept study, was designed to assess the safety and efficacy of lanifibranor (800mg/once daily) in combination with the SGLT2 inhibitor empagliflozin over a 24-week treatment period in patients with non-cirrhotic MASH and T2D.</p>
<p>The study met its primary efficacy endpoint, demonstrating a significant reduction in HbA1c levels in both the lanifibranor arm and the combination arm (lanifibranor with empagliflozin) compared to placebo. Furthermore, therapeutic efficacy with statistical significance was observed across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism, and hepatic steatosis. The improvement in cardiometabolic and hepatic markers of MASH was similar in both active treatment groups. Of note, there was no weight gain in patients receiving the combination of lanifibranor and empagliflozin. The treatment with lanifibranor at a dosage of 800mg/once daily alone or in combination with empagliflozin was well tolerated, with no safety concerns reported.</p>


Biotech

News

General

Inventiva Announces Lanifibranor-Combination Trial Meets Primary Endpoint In MASH Study, Reveals HbA1c Reduction At EASL Summit 2025; Therapeutic Efficacy With Statistical Significance Was Observed Across Multiple Secondary Endpoints, Including Markers Of Liver Injury, Glucose And Lipid Metabolism, And Hepatic Steatosis; No Weight Gain Reported

<p>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has been analyzed by 28 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">13</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $210.82, a high estimate of $232.00, and a low estimate of $185.00. This upward trend is evident, with the current average reflecting a 3.62% increase from the previous average price target of $203.46.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579669_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Alphabet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$232.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Michael Levine</td>
<td>Pivotal Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$212.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$187.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$217.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alphabet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Alphabet compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Alphabet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Alphabet's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alphabet analyst ratings.</strong></a></p>
<h2>Discovering Alphabet: A Closer Look</h2>
<p>Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.</p>
<h3>Unraveling the Financial Story of Alphabet</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Alphabet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.09%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Alphabet's net margin is impressive, surpassing industry averages. With a net margin of <strong>29.8%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Alphabet's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.55%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alphabet's ROA excels beyond industry benchmarks, reaching <strong>6.22%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Alphabet adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

GOOGL

Expert Outlook: Alphabet Through The Eyes Of 28 Analysts

Earnings

Earnings Beats

BANR

Banner Q4 2024 Adj. EPS $1.33 Beats $1.21 Estimate, Sales $160.571M Beat $137.510M Estimate

<p>Ratings for AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) were provided by 26 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">13</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $344.62, along with a high estimate of $480.00 and a low estimate of $66.00. Observing a 42.4% increase, the current average has risen from the previous average price target of $242.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579661_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of AppLovin among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$366.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$375.00</td>
<td>-</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$325.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>James Heaney</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$460.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>David Pang</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$435.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>James Heaney</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$480.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Omar Dessouky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$375.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>James Callahan</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$335.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Jonathan Kees</td>
<td>Daiwa Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>David Pang</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$291.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Sell</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$202.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AppLovin. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AppLovin compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of AppLovin's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into AppLovin's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AppLovin analyst ratings.</strong></a></p>
<h2>Get to Know AppLovin Better</h2>
<p>AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.</p>
<h3>AppLovin: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> AppLovin's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>38.64%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>36.25%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> AppLovin's ROE excels beyond industry benchmarks, reaching <strong>49.55%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> AppLovin's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>8.11%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> AppLovin's debt-to-equity ratio surpasses industry norms, standing at <strong>3.74</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AppLovin Stock: A Deep Dive Into Analyst Perspectives (26 Ratings)

<p>6 analysts have shared their evaluations of Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.67, with a high estimate of $9.00 and a low estimate of $6.00. This current average has increased by 16.21% from the previous average price target of $6.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579653_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Super Group (SGHC)'s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Super Group (SGHC). This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Super Group (SGHC) compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Super Group (SGHC)'s stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Super Group (SGHC)'s market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SGHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Super Group (SGHC) analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Super Group (SGHC)</h2>
<p>Super Group (SGHC) Ltd is a holding company that operates global online sports betting and gaming businesses. The company has two reportable segments, namely Betway and Spin. The majority of the company's revenue comes from the Betway segment, which is a single-brand online sportsbook business with a global reach. Betway has formed strategic partnerships with teams and leagues across the world and recovers sponsorship marketing spend through brand license agreements. The Betway segment generates the majority of the company's revenue.</p>
<h3>Financial Insights: Super Group (SGHC)</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Super Group (SGHC) displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>12.88%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.08%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Super Group (SGHC)'s ROE excels beyond industry benchmarks, reaching <strong>1.54%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Super Group (SGHC)'s ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.87%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Super Group (SGHC)'s debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.13</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SGHC

6 Analysts Have This To Say About Super Group (SGHC)

<p>Across the recent three months, 7 analysts have shared their insights on Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $137.57, with a high estimate of $165.00 and a low estimate of $111.00. This current average reflects an increase of 2.77% from the previous average price target of $133.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579637_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Teradyne. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$111.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$117.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teradyne. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teradyne compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Teradyne's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teradyne's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TER/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teradyne analyst ratings.</strong></a></p>
<h2>Discovering Teradyne: A Closer Look</h2>
<p>Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.</p>
<h3>Key Indicators: Teradyne's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Teradyne's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>4.77%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Teradyne's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>19.75%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.17%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Teradyne's ROA excels beyond industry benchmarks, reaching <strong>3.94%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Teradyne's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Teradyne: Insights From 7 Analyst Reviews

<p>Across the recent three months, 13 analysts have shared their insights on Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Fidelity National Info and provided 12-month price targets. The average target is $98.69, accompanied by a high estimate of $126.00 and a low estimate of $86.00. Surpassing the previous average price target of $89.18, the current average has increased by 10.66%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579623_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Fidelity National Info by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$87.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$103.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fidelity National Info. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Fidelity National Info's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fidelity National Info's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fidelity National Info analyst ratings.</strong></a></p>
<h2>Delving into Fidelity National Info's Background</h2>
<p>Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.</p>
<h3>Financial Insights: Fidelity National Info</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Fidelity National Info's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>3.13%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>8.72%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Fidelity National Info's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.33%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Fidelity National Info's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.65%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Fidelity National Info's debt-to-equity ratio is below the industry average. With a ratio of <b>0.66</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Fidelity National Info's Future

<p>MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) has outperformed the market over the past 5 years by 3.55% on an annualized basis producing an average annual return of 16.73%. Currently, MPLX has a market capitalization of $54.05 billion. </p>
<p><strong>Buying $1000 In MPLX:</strong> If an investor had bought $1000 of MPLX stock 5 years ago, it would be worth <strong>$2,162.39</strong> today based on a price of $53.05 for MPLX at the time of writing.</p>
<h3>MPLX's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579620_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

MPLX

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<p>In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $108.83, a high estimate of $132.00, and a low estimate of $89.00. Observing a 9.56% increase, the current average has risen from the previous average price target of $99.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737579616_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Intra-Cellular Therapies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Intra-Cellular Therapies's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>About Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Key Indicators: Intra-Cellular Therapies's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>39.23%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-15.03%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-2.3%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.99%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of <b>0.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ITCI

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

<p><a href="https://data.epo.org/publication-server/publications/pdf?path=2025/04/DOC/EPNWB1/EP18710585NWB1/EP18710585NWB1.pdf" title="https://data.epo.org/publication-server/publications/pdf?path=2025/04/DOC/EPNWB1/EP18710585NWB1/EP18710585NWB1.pdf">https://data.epo.org/publication-server/publications/pdf?path=2025/04/DOC/EPNWB1/EP18710585NWB1/EP18710585NWB1.pdf</a></p>


SONN

Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".

WIIM

Valero Energy shares are trading lower amid SEC Form 4 filings disclosing several insiders are selling company stock.

NTLA

Intellia Therapeutics shares are trading higher after the company dosed its first patient in the Phase 3 HAELO study.

SDGR

Schrodinger shares are trading higher following mention in a report from Hunterbrook Capital.

Blue Owl Capital shares are trading higher after the company announced the development of its data center in Texas as part of a $2.3 billion JP Morgan financing deal.

<p><a href="https://breakingdefense.com/2025/01/army-kickstarts-possible-recompete-of-microsofts-22-billion-ivas-production-deal/" title="https://breakingdefense.com/2025/01/army-kickstarts-possible-recompete-of-microsofts-22-billion-ivas-production-deal/">https://breakingdefense.com/2025/01/army-kickstarts-possible-recompete-of-microsofts-22-billion-ivas-production-deal/</a></p>


Contracts

KOPN

MSFT

PLTR

Watching Kopin; Shares See Volume As Traders Circulate Article 'Army Kickstarts Possible Recompete Of Microsoft's $22 Billion IVAS Production Deal', "Kopin Has Also Said It's Interested In Completing, While Companies Like Palantir May Also Be Eyeing A Bid."

<p><strong>Amazon.com, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) paid more than $100 million for two parcels of land for two <a href="https://www.benzinga.com/real-estate">data centers in Ohio's Fayette County</a>.</p>
<p>Amazon Data Services Inc. bought 243 acres of land for $60.2 million and another 346 acres for nearly $42.2 million, <a href="https://www.dispatch.com/story/news/2025/01/21/amazon-data-center-ohio-fayette-county-investment/77849706007/">according</a> to a Tuesday Columbus Dispatch report. Construction on the data centers is expected to begin early 2025. </p>
<p>In Fayette County, where Amazon plans to spend $5 billion by 2030, the new site is expected to create more than 100 Amazon jobs and support thousands more across supply chains.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43088798/nancy-pelosi-sells-nvidia-apple-and-loads-up-on-google-parent-alphabet-and-amazon-calls">Nancy Pelosi Sells Nvidia, Apple And Loads Up On Google-Parent Alphabet And Amazon Calls</a></strong></p>
<h2 class="wp-block-heading"><strong>More To Come For Ohio&#8217;s $10-Billion Data Centers</strong></h2>
<p>The two parcels of land represent the first site of Amazon Web Service&#8217;s planned $10 billion investment in data centers by 2030 across Ohio, which will include up to eight more locations in the Buckeye state, according to the company.</p>
<p>&#8220;As AWS continues to invest in Ohio, we are grateful to the local leadership in Fayette County who support our ability to grow and innovate on behalf of our customers,&#8221; stated <strong>Roger Wehner</strong>, VP of economic development at Amazon Web Services. &#8220;We look forward to leveraging our strong public and private partnerships to extend the impact of our investment across the state, and bring new educational and workforce opportunities to the next generation of tech talent."</p>
<h2 class="wp-block-heading"><strong>Unprecedented Demand For Energy</strong></h2>
<p>In 2024, Google and Amazon added nearly 400 megawatts of data center capacity around the greater Columbus area. It was the most capacity added to any city in the United States, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-10-17/unexpected-surge-in-us-power-demand-draws-comparison-to-wwii-era?sref=TBDibEcD">reported</a> at the time.</p>
<p>"The last time the US electricity industry saw unexpected new demand growth like this was during World War II,"&nbsp;wrote <strong>Chris Seiple,</strong> Wood Mackenzie's vice chair of power and renewables in an October 2024 <a href="https://www.woodmac.com/horizons/gridlock-demand-dilemma-facing-us-power-industry/?__FormGuid=81d8a1b9-fba3-4634-bdc1-67c626a6af21&amp;__FormLanguage=en&amp;__FormSubmissionId=c9e8fc16-4b7c-45ed-9330-d1ecf93f34be" target="_blank" rel="noreferrer noopener">report</a>. Wood Mackenzie is a global provider of data and analytics solutions.</p>
<p>The surge in data centers means Ohio is expected to eat up so much electricity that demand for power in the region will be similar to all of Manhattan by 2030, according to <strong>American Electric Power</strong>.</p>
<p>"Demand for computing power from data centers, which require enormous amounts of electricity, is being fueled by artificial intelligence and other new technologies,&#8221;  said <strong>Marc Reitter</strong>, AEP Ohio president and COO in a May 2024 <a href="https://www.aepohio.com/company/news/view?releaseID=9539">press release</a>. &#8220;AEP Ohio is seeing unprecedented demand from data center customers, especially in the central Ohio area.&#8221;</p>
<p>Meanwhile, the Electric Power Research Institute projects that by 2030, data centers could account for as much as 9% of the electricity produced in the entire U.S., more than twice their current usage. The non-profit energy research organization raises concerns over regional supply challenges.</p>
<p>&#8220;The data center boom requires closer collaboration between large data center owners and developers, utilities, government, and other stakeholders to ensure that we can power the needs of AI while maintaining reliable, affordable power to all customers," <a href="https://www.epri.com/about/media-resources/press-release/q5vu86fr8tkxatfx8ihf1u48vw4r1dzf#:~:text=According%20to%20a%20new%20study,supply%20challenges%2C%20among%20other%20issues.">said</a> <strong>David Porter</strong>, EPRI&#8217;s VP of electrification and sustainable energy.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43137590/microsoft-invests-in-carbon-credits-to-restore-amazon-rainforest-faces-challenges-from-data-center-growth-trumps-fossil-fuel-focus"><strong>Microsoft Invests In Carbon Credits To Restore Amazon Rainforest, Faces Challenges From Data Center Growth, Trump&#8217;s Fossil Fuel Focus</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Markets

AMZN

Amazon's $100M Land Deal Launches Its $10-Billion Data Center Project In Ohio

Kopin shares are trading higher amid a report suggesting the company may be interested in competing for an Army contract.

PG&E shares are trading lower amid weakness in utility stocks. The stock recently was under pressure amid CA fires.

<p><a href="https://x.com/AOC/status/1882158448244330832" title="https://x.com/AOC/status/1882158448244330832">https://x.com/AOC/status/1882158448244330832</a></p>


Politics

Alexandria Ocasio-Cortez Posts On X "GEO Group is the nation's largest private prison company. Look for the members of Congress who either buy their stock or take their money and vote YES on this bill. They are not voting for you - they're voting to enrich themselves. It's corruption in plain sight."

<p>With <a href="https://www.benzinga.com/topic/interest-rates">ultra-low interest rates</a> firmly in the rearview mirror,<strong> Jeff Weniger</strong>, Head of Equity Strategy at WisdomTree, has a clear message for investors: &#8220;Anything in the high-4s on a 10-year Treasury rate puts the <strong>S&amp;P 500</strong>'s earnings yield at a level where it either barely exceeds or does not exceed the risk-free yield.&#8221;</p>
<p>In other words, it&#8217;s time to rethink the Growth vs. Value debate.</p>
<p>In an exclusive interview with Benzinga, Weniger said that investors in the "higher for longer" camp should focus on Value stocks. ETFs such as the <strong>Vanguard Value ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>), the <strong>SPDR Select Sector Fund &#8211; Energy</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), the <strong>Vanguard Small-Cap Value ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VBR#NYSE">VBR</a>) and the <strong>iShares Select Dividend ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>) provide exposure to value equity in the U.S.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/01/43059744/exclusive-can-sp-500-repeat-large-gains-from-donald-trumps-first-term-a-second-time-around-readers-say-this-return-range-most-likely" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Can S&amp;P 500 Repeat Large Gains From Donald Trump&#8217;s First Term A Second Time Around? Readers Say This Return Range Most Likely</a></strong></p>
<p>As rates rise, the yields on Treasury bonds become more competitive with stock market earnings, making growth stocks, which have long outperformed, much less attractive. In such a scenario, investors in growth-focused ETFs such as the <strong>Invesco QQQ Trust, Series 1</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and the <strong>Vanguard Growth ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VUG#NYSE">VUG</a>) should remain wary of their holdings.</p>
<p>"In that scenario, which is a live one, investors need to reassess the more speculative portions of their portfolio," he said.</p>
<h2 class="wp-block-heading">Tariff Tension &amp; Its Surprising Impact</h2>
<p>While tariffs continue to be a topic of concern, Weniger suggests that much of this risk is already baked into the market. &#8220;Tariff risk is one of the most priced-in risks we have seen for some time,&#8221; he explained.</p>
<p>Reshoring efforts, which began during the pandemic, are unlikely to be significantly affected by new tariffs. So, if you&#8217;re expecting a major tariff shock to upend the market, Weniger believes the impact may be much smaller than anticipated.</p>
<h2 class="wp-block-heading">Inflation's Hidden Risks: Housing Edition</h2>
<p>Beyond energy prices, Weniger identifies a potentially overlooked inflation risk: housing. &#8220;The market needs to contend with the very real arithmetic of Owners Equivalent Rent in the CPI calculation,&#8221; he said.</p>
<p>Even if home prices stagnate or fall, the inflated housing costs will continue to push the CPI higher.</p>
<h2 class="wp-block-heading">Navigating Market Sentiment</h2>
<p>With macro uncertainties looming, Weniger advises investors to manage their risk carefully. &#8220;Sentiment is arguably bubbly in certain pockets of U.S. markets and downright moribund in others,&#8221; he adds, suggesting that international stocks might be a safer bet while scaling back exposure to U.S. equities in the current volatile climate.</p>
<p>The <strong>Vanguard FTSE Developed Markets ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEA#NYSE">VEA</a>), the <strong>iShares Core MSCI EAFE ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEFA#BATS">IEFA</a>) and the <strong>WisdomTree International Hedged Quality Dividend Growth Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHDG#NYSE">IHDG</a>) provide exposure to international equity.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/25/01/43083803/market-bets-on-trumps-tariff-announcement-plummet-dollar-falls-whats-going-on">Market Bets On Trump&#8217;s Tariff Announcement Plummet, Dollar Falls: What&#8217;s Going On?</a></strong></li>
</ul>
<p><em>Image created using artificial intelligenc via Midjourney.</em></p>


Government

Long Ideas

Regulations

Broad U.S. Equity ETFs

Exclusives

Interview

ETFs

iShares Dow Jones Select Dividend Index Fund

Comments

Bukit Jalil Global Acquisition 1 Ltd. - Rights

Bukit Jalil Global Acquisition 1 Ltd. - Rights (BUJAR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga